Complex therapy for patients with ankylosing spondylitis with mixed anxiety–depressive disorder

Abstract

Objective. The study aimed to evaluate the effect of therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) in combination with melatonin on the dynamics of the quality of life (QOL), clinical and laboratory activity, and mixed anxiety– depressive disorder (MADD) in patients with ankylosing spondylitis (AS).Materials and methods. The study involved 65 patients with AS and RTDS. Patients from Group I (n=32) were prescribed melatonin at a dose of 3 mg per day at night, 30–40 minutes before bedtime, in addition to standard AS therapy. Patients from Group II (n = 33) received standard therapy. 8 weeks after, the dynamics of QOL indicators, clinical and laboratory activity, and the severity of MADD in patients from both groups were evaluated.Results. The application of melatonin in addition to standard therapy in patients with AS and MADD provided a statistically significant improvement in the functional and clinical-laboratory data (frequency and severity of anxiety and depression, pain syndrome indicators, ESR, CRP, integrative indicators of physical and psychological components of health).Conclusion. The application of melatonin in complex therapy for patients with AS and MADD contributes to the improvement of clinical and laboratory parameters, psychoemotional state, and QOL of this category of patients.

Keywords

• ankylosing spondylitis
• mixed anxiety–depressive disorder
• quality of life
• melatonin